About me
Albert Hsia leads Oncology and Immunology business development at Merck’s Boston Hub, focusing on innovative opportunities for partnership and M&A that can accelerate the development of breakthrough medicines for the most challenging diseases.
Albert came to Merck with broad business and management experience in biotech, from company formation to exit and from early discovery to late clinical development, at companies including Synta Pharmaceuticals (now Madrigal Pharmaceuticals), Genewave (now Hologic), Atlas Venture, and Disarm Therapeutics (now Lilly).